Versuchen GOLD - Frei
Addressing Women's Health with Portable Devices
BioSpectrum Asia
|BioSpectrum Asia June 2025
The confluence of innovation, affordability, and accessibility creates a compelling market proposition for healthcare providers, diagnostic chains, corporate wellness programmes, and public health systems alike in cancer care with focus on women's cancer in Asia.
-
Cancer continues to be one of the leading causes of death worldwide, and in Asia, where nearly half of the world’s population resides, the burden is particularly profound. Among women, breast and cervical cancer are among the most prevalent, yet also the most preventable when detected early. However, vast disparities in healthcare infrastructure, especially in lowand middle-income countries, often delay diagnosis and treatment. It is here that accurate and affordable cancer screening, enabled by portable medical devices, offers transformative potential. This is a critical health issue and also a strategic growth opportunity.
Addressing a Critical Need in Women’s Health
Asia presents a diverse and complex healthcare landscape. In countries like India, Indonesia, and the Philippines, rural populations still face challenges in accessing even basic diagnostic services. The prevalence of late-stage detection in these regions is high, and survival rates are correspondingly low. For breast and cervical cancers, which can be effectively managed if detected early, the lack of early screening is a major contributor to mortality.
Portable screening devices are uniquely suited to address this challenge. Compact, easy-to-use, and powered by battery or mobile technologies, these tools can be deployed outside of traditional hospital settings. From urban clinics to rural health camps, they bring early detection capability to the point of need. In the case of breast cancer, technologies like iBreastExam, a non-invasive, radiation-free device, allow community health workers to perform standardised breast exams without the need for expensive imaging infrastructure. Similarly, portable colposcopes and HPV test kits are changing the game for cervical cancer screening.
Diese Geschichte stammt aus der BioSpectrum Asia June 2025-Ausgabe von BioSpectrum Asia.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON BioSpectrum Asia
BioSpectrum Asia
Seeing Opportunity in Ophthalmology
Asia-Pacific is emerging as one of the most active regions for ophthalmology innovation. In recent months, a wave of cross-border partnerships and licensing deals has underscored both the scale of unmet need in eye disease and the region's growing ambition to play a larger role in treatment development. From glaucoma and retinal disorders to dry eye disease and childhood myopia, companies across pharma, biotech, and medtech are increasingly accelerating clinical progress.
6 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Reshaping Asia's Healthcare with mRNA Innovation
The COVID-19 pandemic acted as both a challenge and a catalyst, serving as a testbed that fundamentally reshaped the biotechnology landscape across Asia and beyond. What emerged during this period was not just a breakthrough moment for mRNA, but the early foundation of a broader transformation that is still unfolding.
2 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Momentum in Motion: What Will Shape APAC's Life Sciences Landscape in 2026?
Asia-Pacific's life sciences sector is growing rapidly, driven by its scale, diversity and resilience. Accelerating demographic change and strong investment in innovation position the region to outpace global growth and shape the future of healthcare.
5 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
The Future of mRNA Is Being Built in APAC
Beyond scientific advancement, mRNA represents a strategic opportunity shaped by policy stability, public investment and regional collaboration. Across APAC, governments are increasingly recognising that supportive regulatory frameworks and long-term funding can serve as powerful competitive advantages, attracting global capital and talent. While political dynamics in the United States have slowed momentum, experts emphasise that the science underpinning mRNA technology remains sound. To fully realise its potential, the region will need greater coordination across borders, including regulatory harmonisation and joint development pathways, to build a resilient mRNA ecosystem capable of addressing shared health challenges and driving long-term innovation.
25 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
How Precision Medicine Is Reshaping Cancer Care
Despite major advances in cancer detection and treatment, high recurrence rates and progression to advanced disease continue to challenge outcomes across Asia-making precision medicine a critical catalyst for shifting cancer care from disease management toward treat-to-cure. By leveraging molecular insights, biomarker testing and collaborative healthcare ecosystems, precision medicine offers the potential to deliver more effective, personalised and sustainable cancer care for patients across the region.
2 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Repligen introduces next-generation chromatography resins
Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, has announced the launch of three new high-performance chromatography resins:
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Hanahealth by DSS Imagetech launches GERI Time-Lapse Incubator in India
Hanahealth by DSS Imagetech, the authorised partner of Sydney-based Genea Biomedx, has launched the advanced GERI Time-Lapse Incubator pan India. GERI, the nextgeneration Time Lapse embryo culture system from Genea Biomedx, is ideal for IVF clinics, labs adopting digital transformation, centres working toward accreditation, and research-focused fertility groups as it enables them to modernise their processes and improve IVF outcomes.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Biotechnology to Drive Next Industrial Revolution: Dr Jitendra Singh
\"Biotechnology will play a defining role in shaping the next industrial revolution and will be a key driver of global and Indian economic growth\", said Dr Jitendra Singh, the Union Minister of State (Independent Charge) for Science and Technology.
1 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Cartherics names Dr lan Nisbet as CEO
Australia-based Cartherics, a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women's diseases, with lead programmes in ovarian cancer and endometriosis, has announced the appointment of Dr Ian Nisbet as Chief Executive Officer, as part of a planned leadership transition.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Neurophet ropes in Josh Cohen as Head of Americas Business
South Korea-based Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, has appointed Josh Cohen, a veteran executive from leading global medical device companies, as new Head of Americas Business.
1 min
BioSpectrum Asia Jan 2026
Listen
Translate
Change font size
